BRISBANE, Calif., Jan. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 32nd Annual J. P. Morgan Healthcare Conference in San Francisco on January 13, 2014, at 12:00 Noon EST / 9:00 a.m. PST.
(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investors page of InterMune’s corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune’s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.
SOURCE InterMune, Inc.
Help employers find you! Check out all the jobs and post your resume.
